Navigation Links
Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
Date:9/11/2013

Rockville, MD (PRWEB) September 11, 2013

There is a significant unmet need for accurate and precise biomarker tests for clinical trials, drug development and medical research. V-PLEX simultaneously measures multiple biomarkers using assays that are grouped into panels for optimal and consistent performance. The V-PLEX immunoassay menu focuses on emerging biomarkers that are generally not available on traditional diagnostics platforms, giving researchers access to new types of tests.

“We’re very excited that the life science and clinical research community will now have access to new biomarker tests through V-PLEX,” said Jacob Wohlstadter, President and CEO. “The lack of validated tests for biomarkers has challenged pharmaceutical companies and been a major limitation for important medical research. Together with our recently launched QuickPlexSQ 120 instrument, V-PLEX offers unprecedented access to high-quality immunoassays in a flexible and affordable format.”

Validated tests enable long-term programs like clinical trials and epidemiological studies by providing sustainable, reliable measurements of clinically significant markers. These tests have defined, rigorous specifications for analytical performance, and each new lot passes strict requirements before release. Results from validated tests are viewed with greater confidence and are often required for regulatory approvals.

“The practical implications of V-PLEX are significant, particularly for laboratories and CROs that run biomarker tests as their primary business” said Dr. James Wilbur, General Manager. “In the absence of available tests, these laboratories must bear the burden of developing their own tests and conducting formal validations, which is simply unaffordable for many markers. With V-PLEX, these laboratories can now offer a wide menu of biomarkers in a fully-validated format, and, through the use of V-PLEX panels, reduce their labor, costs and sample consumption even further.”

V-PLEX immunoassays, using MSD’s proprietary electrochemiluminescence (ECL) MULTI-ARRAY® technology, are developed under rigorous design control and are fully validated according to “Fit for Purpose” principles. They are compatible with either MSD’s SECTOR® or QuickPlex instrument lines. The initial menu of V-PLEX immunoassays includes the most important cytokines, chemokines, and Alzheimer’s disease biomarkers.

For more information on V-PLEX immunoassays, call Customer Service at 1-240-314-2795; email customerservice@mesoscale.com; or visit http://www.mesoscale.com/V-PLEX.

Read the full story at http://www.prweb.com/releases/immunoassay/news/prweb11109813.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. CPUsage Launches Massive Scale Cloud Computing Platform at TechCrunch Disrupt
2. Breakthrough in sensing at the nanoscale
3. LIMS 24/7 and Ayrris: Big-Data Lab Management for Production-Scale NGS
4. Broad-scale genome tinkering with help of an RNA guide
5. Meso Scale Discovery Launches New Quickplex™ SQ 120 Multiplex Immunoassay Instrument
6. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
7. Cross-Cultural Qualitative Research for Simultaneous Scale Development, New Life Science Webinar Hosted by Xtalks
8. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
9. Study led by GW professor provides better understanding of waters freezing behavior at nanoscale
10. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
11. CIC nanoGUNE launches Simune, an atomic-scale simulations service for companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in ... Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced today ... its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. , ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy ... infections through education and advocacy. Founded in 2010 in memory of a single-parent ... the foundation has become the most-consulted source for patient-focused information on C. diff ...
(Date:4/19/2017)... and PUNE, India , April 19, 2017 /PRNewswire/ ... "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the global ... $12,858 million by 2022, registering a CAGR of 9.6% from 2016 to 2022. ... ... ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 ... specialty finance firm that provides senior debt to ... the closing of a $20 million senior secured ... orthobiologics company engaged in the development and commercialization ... of orthopedic injuries. Cerapedics, lead product, ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
Breaking Biology News(10 mins):